Vivos Therapeutics, Inc.
General ticker "VVOS" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $25.3M (TTM average)
Vivos Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -32.6%.
Estimated limits based on current volatility of 5.3%: low 0.66$, high 0.73$
Factors to consider:
- Total employees count: 154 as of 2022
- Top business risk factors: Economic downturns and volatility, Pandemic risks, Inflation, Supply chain disruptions, Regulatory and compliance
- Current price 25.9% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.87$, 2.89$]
- 2026-12-31 to 2027-12-31 estimated range: [0.65$, 2.22$]
Financial Metrics affecting the VVOS estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of -0.30 <= -0.16
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
Short-term VVOS quotes
Long-term VVOS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $13.80MM | $15.03MM | $17.44MM |
| Operating Expenses | $31.10MM | $26.20MM | $37.34MM |
| Operating Income | $-17.30MM | $-11.17MM | $-19.89MM |
| Non-Operating Income | $3.71MM | $0.04MM | $-1.34MM |
| Income(Loss) | $-13.58MM | $-11.14MM | $-21.23MM |
| Net Income(Loss)* | $-13.58MM | $-11.14MM | $-21.17MM |
| Stockholders Equity | $0.41MM | $7.95MM | $-1.49MM |
| Assets | $10.73MM | $15.28MM | $25.15MM |
| Operating Cash Flow | $-11.95MM | $-12.69MM | $-15.26MM |
| Capital expenditure | $0.80MM | $0.57MM | $2.34MM |
| Investing Cash Flow | $-0.85MM | $-0.57MM | $-7.53MM |
| Financing Cash Flow | $10.92MM | $17.88MM | $18.56MM |
| Earnings Per Share** | $-11.14 | $-2.22 | $-2.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.